PT - JOURNAL ARTICLE AU - Brian T. Garibaldi AU - Jacob Fiksel AU - John Muschelli AU - Matthew Robinson AU - Masoud Rouhizadeh AU - Paul Nagy AU - Josh H. Gray AU - Harsha Malapati AU - Mariam Ghobadi-Krueger AU - Timothy M. Niessen AU - Bo Soo Kim AU - Peter M. Hill AU - M. Shafeeq Ahmed AU - Eric D. Dobkin AU - Renee Blanding AU - Jennifer Abele AU - Bonnie Woods AU - Kenneth Harkness AU - David R. Thiemann AU - Mary G. Bowring AU - Aalok B. Shah AU - Mei-Cheng Wang AU - Karen Bandeen-Roche AU - Antony Rosen AU - Scott L. Zeger AU - Amita Gupta TI - Patient trajectories and risk factors for severe outcomes among persons hospitalized for COVID-19 in the Maryland/DC region AID - 10.1101/2020.05.24.20111864 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.24.20111864 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.24.20111864.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.24.20111864.full AB - Background Risk factors for poor outcomes from COVID-19 are emerging among US cohorts, but patient trajectories during hospitalization ranging from mild-moderate, severe, and death and the factors associated with these outcomes have been underexplored.Methods We performed a cohort analysis of consecutive COVID-19 hospital admissions at 5 Johns Hopkins hospitals in the Baltimore/DC area between March 4 and April 24, 2020. Disease severity and outcomes were classified using the WHO COVID-19 disease severity ordinal scale. Cox proportional-hazards regressions were performed to assess relationships between demographics, clinical features and progression to severe disease or death.Results 832 COVID-19 patients were hospitalized; 633 (76.1%) were discharged, 113 (13.6%) died, and 85 (10.2%) remained hospitalized. Among those discharged, 518 (82%) had mild/moderate and 116 (18%) had severe illness. Mortality was statistically significantly associated with increasing age per 10 years (adjusted hazard ratio (aHR) 1.54; 95%CI 1.28-1.84), nursing home residence (aHR 2.13, 95%CI 1.41-3.23), Charlson comorbidity index (1.13; 95% CI 1.02-1.26), respiratory rate (aHR 1.13; 95%CI 1.09-1.17), D-dimer greater than 1mg/dL (aHR 2.79; 95% 1.53-5.09), and detectable troponin (aHR 2.79; 95%CI 1.53-5.09). In patients under 60, only male sex (aHR 1.7;95%CI 1.11-2.58), increasing body mass index (BMI) (aHR1.25 1.14-1.37), Charlson score (aHR 1.27; 1.1-1.46) and respiratory rate (aHR 1.16; 95%CI 1.13-1.2) were associated with severe illness or death.Conclusions A combination of demographic and clinical features on admission is strongly associated with progression to severe disease or death in a US cohort of COVID-19 patients. Younger patients have distinct risk factors for poor outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received funding from from Hopkins inHealth, the Johns Hopkins Precision Medicine Program.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the IRBs at all of the participating hospitals in the health system. It was deemed to be minimal risk and a waiver of informed consent was granted.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data for this study is maintained in the Johns Hopkins Precision Medicine Analytics Platform (PMAP).